Shares of Mallinckrodt plc MNK crashed 24.2% after the company filed suit in federal district court against the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to protect Medicaid patient access to Acthar.
The lawsuit was filed against the agency’s decision, which required Mallinckrodt to change the base date average manufacturer price (AMP) used to calculate Medicaid drug rebates for Acthar.
Through the lawsuit, the company challenges CMS' unexplained and unlawful reversal of its repeated 2012 written authorizations on calculation of Medicaid rebates for Acthar.
The company has decided to seek court intervention to ensure that CMS follows Administrative Procedure Act and other legal requirements, after repeated failed attempts to solve the matter through discussions.
Acthar Gel, which became part of the company’s portfolio following the Questcor acquisition, is currently approved for 19 indications. It is the lead drug in Mallinckrodt’s portfolio.
Per Mallinckrodt, the attempted reversal, which CMS seeks unlawfully to make retroactive, would substantially eliminate Medicaid net sales of Acthar Gel.
If the court doesn’t intervene, Mallinckrodt would lose Medicaid net sales for Acthar Gel, which currently contributes 10% to total Acthar sales. This in turn also jeopardizes the company’s annual guidance of raking in more than $1 billion of Acthar sales in 2019, with the potential for retroactive non-recurring charges going up to $600 million.
We remind investors that Mallinckrodt was in the news last month as there were allegations against Acthar’s previous owner, Questcor, for conducting illegal sales and marketing activities related to Acthar. Per the company, the original action was filed in 2012, prior to Mallinckrodt's ownership of Acthar Gel, and consist of two complaints filed by former Questcor employees.
The U.S. Department of Justice (DOJ) elected to join an existing civil False Claims Act case against the company. However, since these allegations were made prior to Mallinckrodt's acquisition of Acthar Gel, the company does not expect any impact on its business today due to these.
Mallinckrodt’s stock has plunged 37.5% in the year so far compared with the industry’s decline of 4.6%.
Acthar generated sales of $223.9 million in the first quarter. We expect the lawsuit to weigh on shares until resolved.
Zacks Rank & Key Picks
Mallinckrodt currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks are Bristol-Myers Squibb Co. BMY, Roche RHHBY and Celgene Corp. CELG. While Bristol-Myers sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers’ earnings per share estimates have increased from $4.78 to $5.03 for 2020 in the past 60 days.
Roche’s earnings per share estimates have increased from $2.35 to $2.40 for 2019 in the past 60 days.
Celgene’s earnings estimates have moved up 3 cents to $10.74 over the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Mallinckrodt public limited company (MNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.